Clinical relevance of changes in bone metabolism in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 16, Issue 44, 2010, Pages 5536-5542

  Miheller, Pal ^a   Lorinczy, Katalin ^a   Lakatos, Peter Laszlo ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Crohn's disease; Inflammatory bowel disease; Osteopenia; Osteoporosis; Prevention

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALENDRONIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITONIN; CALCIUM; CORTICOSTEROID; IBANDRONIC ACID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; OPIATE; OSTEOCALCIN; PREDNISOLONE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

BONE DENSITY; BONE DISEASE; BONE MASS; BONE METABOLISM; CALCIUM INTAKE; CLINICAL FEATURE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; ENTERITIS; EPIDEMIOLOGICAL DATA; FOLLOW UP; FRACTURE; GASTROINTESTINAL TRACT EXAMINATION; GOLD STANDARD; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE MODIFICATION; LOW BONE MINERAL DENSITY; LOW DRUG DOSE; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PREVENTION STUDY; RISK; RISK FACTOR; SCREENING TEST; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT PLANNING; ULCERATIVE COLITIS; VERTEBRA FRACTURE;

EID: 78649696461     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i44.5536     Document Type: Editorial

References (71)

1. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 410-415
2. Szathmári M, Prónai L, Tulassay Z. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1998; 93: 848-849
3. Pigot F, Roux C, Chaussade S, Hardelin D, Pelleter O, Du Puy Montbrun T, Listrat V, Dougados M, Couturier D, Amor B. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37: 1396-1403
4. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646-650
5. Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 268-275
6. Robinson RJ, al-Azzawi F, Iqbal SJ, Kryswcki T, Almond L, Abrams K, Mayberry JF. Osteoporosis and determinants of bone density in patients with Crohn's disease. Dig Dis Sci 1998; 43: 2500-2506
7. Schoon EJ, van Nunen AB, Wouters RS, Stockbrügger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol Suppl 2000; 43-47
8. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 250-256
9. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 228-233
10. Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 313-319
11. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 1031-1039
12. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998; 93: 1483-1490
13. Poturoglu S, Balkan F, Karaali ZE, Ibrisim D, Yanmaz S, Aktuglu MB, Alioglu T, Kendir M. Relationship between bone mineral density and clinical features in patients with inflammatory bowel disease: a local study in Turkish population. J Int Med Res 2010; 38: 62-68
14. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936
15. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989-995
16. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-882
17. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 795-799
18. Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123: 468-475
19. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac Disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol 2002; 156: 1-10
20. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 2000; 46: 176-181
21. Stockbrügger RW, Schoon EJ, Bollani S, Mills PR, Israeli E, Landgraf L, Felsenberg D, Ljunghall S, Nygard G, Persson T, Graffner H, Bianchi Porro G, Ferguson A. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1519-1527
22. Klaus J, Armbrecht G, Steinkamp M, Brückel J, Rieber A, Adler G, Reinshagen M, Felsenberg D, von Tirpitz C. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002; 51: 654-658
23. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000
24. Bernstein CN, Blanchard JF, Metge C, Yogendran M. The association between corticosteroid use and development of fractures among IBD patients in a population-based database. Am J Gastroenterol 2003; 98: 1797-1801
25. Siffledeen JS, Siminoski K, Jen H, Fedorak RN. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 721-728
26. Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol 1999; 34: 696-702
27. Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population- based prospective two-year follow-up study. Scand J Gastroenterol 2004; 39: 145-153
28. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795-841
29. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46 Suppl 1: i1-i8
30. Haugeberg G, Vetvik K, Stallemo A, Bitter H, Mikkelsen B, Stokkeland M. Bone density reduction in patients with Crohn disease and associations with demographic and disease variables: cross-sectional data from a population-based study. Scand J Gastroenterol 2001; 36: 759-765
31. Kuisma J, Luukkonen P, Järvinen H, Kahri A, Färkkilä M. Risk of osteopenia after proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 2002; 37: 171-176
32. Robinson RJ, Iqbal SJ, Al-Azzawi F, Abrams K, Mayberry JF. Sex hormone status and bone metabolism in men with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 21-25
33. Silvennoinen JA, Karttunen TJ, Niemelä SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37: 71-76
34. Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2009; 21: 159-166
35. Miheller P, Muzes G, Rácz K, Blázovits A, Lakatos P, Herszényi L, Tulassay Z. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 2007; 13: 1379-1384
36. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244: 271-292
37. Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Haptén-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrügger RW. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol 2005; 3: 113-121
38. van Hogezand RA, Bänffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy NA. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos Int 2006; 17: 535-542
39. Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. Dig Dis 2006; 24: 201-206
40. Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 417-422
41. Sonnenberg A, Ehms H, Sonnenberg GE, Strohmeyer G. 25-hydroxycholecalciferol serum levels in patients with Crohn's disease. Acta Hepatogastroenterol (Stuttg) 1977; 24: 293-295
42. Driscoll RH Jr, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83: 1252-1258
43. Compston JE, Creamer B. Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. Gut 1977; 18: 171-175
44. Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, Legnani P, George J, Young J. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am J Gastroenterol 2006; 101: 1546-1550
45. Andreassen H, Hylander E, Rix M. Gender, age, and body weight are the major predictive factors for bone mineral density in Crohn's disease: a case-control cross-sectional study of 113 patients. Am J Gastroenterol 1999; 94: 824-828
46. Nemetz A, Tóth M, García-González MA, Zágoni T, Fehér J, Peña AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 2001; 49: 644-649
47. Nanes MS. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 2003; 321: 1-15
48. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54: 479-487
49. Vahedi H, Momtahen S, Olfati G, Abtahi A, Hosseini S, Kazzazi AS, Khademi H, Rashtak S, Khaleghnejad R, Tabrizian T, Hamidi Z, Nouraie M, Malekzadeh F, Merat S, Nasseri-Moghaddam S, Sotoudehmanesh R, Larijani B. A case-control study on risk factors of osteoporosisin patients with Crohn's disease. Arch Iran Med 2009; 12: 570-575
50. Silvennoinen JA, Lehtola JK, Niemelä SE. Smoking is a risk factor for osteoporosis in women with inflammatory bowel disease. Scand J Gastroenterol 1996; 31: 367-371
51. Sampson HW. Alcohol and other factors affecting osteoporosis risk in women. Alcohol Res Health 2002; 26: 292-298
52. Robinson RJ, Krzywicki T, Almond L, al-Azzawi F, Abrams K, Iqbal SJ, Mayberry JF. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115: 36-41
53. NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272: 1942-1948
54. Sentipal JM, Wardlaw GM, Mahan J, Matkovic V. Influence of calcium intake and growth indexes on vertebral bone mineral density in young females. Am J Clin Nutr 1991; 54: 425-428
55. Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 2468-2473
56. Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm Bowel Dis 2002; 8: 87-92
57. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 609-614
58. Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebocontrolled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment Pharmacol Ther 1996; 10: 777-786
59. Miheller P, Muzes G, Hritz I, Lakatos G, Pregun I, Lakatos PL, Herszényi L, Tulassay Z. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009; 15: 1656-1662
60. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34: 1543-1546
61. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119: 639-646
62. Henderson S, Hoffman N, Prince R. A double-blind placebocontrolled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. Am J Gastroenterol 2006; 101: 119-123
63. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17: 807-816
64. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians, 2002
65. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005; 100: 2031-2035
66. Miheller P, Muzes G, Zágoni T, Tóth M, Rácz K, Tulassay Z. [Improvement of bone metabolism after infliximab therapy in Crohn's disease] Orv Hetil 2005; 146: 1477-1480
67. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, doubleblind, placebo-controlled extension trial. Arthritis Rheum 2001; 44: 202-211
68. Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 699-704
69. Bauer DC, Sklarin PM, Stone KL, Black DM, Nevitt MC, Ensrud KE, Arnaud CD, Genant HK, Garnero P, Delmas PD, Lawaetz H, Cummings SR. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 1999; 14: 1404-1410
70. Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996; 38: 223-228
71. Von Tirpitz C, Pischulti G, Klaus J, Rieber A, Brückel J, Böhm BO, Adler G, Reinshagen M. [Pathological bone density in chronic inflammatory bowel diseases--prevalence and risk factors] Z Gastroenterol 1999; 37: 5-12